Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

38.10
Delayed Data
As of 4:00pm ET
 +0.09 / +0.24%
Today’s Change
19.06
Today|||52-Week Range
40.14
+72.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$3.0B

Company Description

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Contact Information

Dicerna Pharmaceuticals, Inc.
75 Hayden Avenue
Lexington Massachusetts 02421
P:(617) 621-8097
Investor Relations:

Employees

Shareholders

Other institutional46.10%
Mutual fund holders33.14%
Individual stakeholders15.19%

Top Executives

Douglas M. FambroughPresident, Chief Executive Officer & Director
James B. WeissmanChief Operating Officer & Executive Vice President
Douglas W. PagánChief Financial Officer
Bob D. BrownChief Scientific Officer
Shreeram AradhyeChief Medical Officer & Executive Vice President